EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease

Austin M Wheeler iD, Joshua F Baker, Thomas R Riley iD, Tate M Johnson iD, Yangyuna Yang, Punyasha Roul, Katherine D Wysham iD, Grant W Cannon iD, Gary Kunkel, Gail Kerr iD, Dana P Ascherman iD, Paul Monach iD und 7 weitere

Arthritis & Rheumatology · 2025-08 · 77 (8) · 971-980

DOI: 10.1002/art.43149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 07.04.2025. Verfasst von Austin M Wheeler und 18 weiteren Autor:innen. Beteiligte Einrichtung: VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Lung Diseases, Interstitial. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, CSRD VA, RRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) is a significant cause of morbidity and mortality among patients with RA, yet effective risk stratification for RA‐ILD is lacking. We sought to characterize unique peripheral blood biomarker signatures in RA that could improve RA‐ILD discrimination beyond clinical and genetic risk factors.

Methods

We performed a cross‐sectional study of participants in the Veterans Affairs Rheumatoid Arthritis Registry. ILD was validated through systematic record review. Autoantibodies (n = 14), proinflammatory cytokines/chemokines (n = 36), adipokines (n = 3), alarmins (n = 3), and matrix metalloproteinases (n = 9) were measured from banked serum or plasma. MUC5B rs35705950 genotyping was obtained via microarray. Principal component (PC) analysis was performed to derive unique biomarker signatures. Logistic regression was used to compare models predicting RA‐ILD presence using combinations of clinical, peripheral biomarker, and genetic variables.

Results

Among 2,001 participants with RA (88.7% male, mean age 63.7 years), 121 (6.4%) had RA‐ILD. A total of 15 PCs were identified, with 8 significantly associated with RA‐ILD after adjusting for clinical factors. These eight included biomarker themes of innate and allergic responses, autoantibodies (anti–cyclic citrullinated peptide, rheumatoid factor, anti–malondialdehyde‐acetaldehyde adduct), adipokines, alarmins, tissue remodeling, and neutrophil chemotaxis. Models with PCs (area under the receiver operating characteristic curve [AUC] 0.739) and PCs with MUC5B (AUC 0.751) outperformed clinical risk factors alone (AUC 0.630; P < 0.001).

Conclusion

Peripheral biomarker signatures are associated with RA‐ILD and improve RA‐ILD identification beyond clinical risk factors. In addition to demonstrating the potential for peripheral biomarkers to aid RA‐ILD risk stratification, these findings suggest diverse pathways are involved in RA‐ILD pathogenesis. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidLung Diseases, InterstitialHumansMaleFemaleBiomarkersMiddle AgedCross-Sectional StudiesAgedAutoantibodiesMucin-5BAdipokinesCytokinesMatrix Metalloproteinases

Substanzen

BiomarkersAutoantibodiesMucin-5BMUC5B protein, humanAdipokinesCytokinesMatrix Metalloproteinases

Autor:innen und Institutionen

  • VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha.
  • University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia.
  • University of Nebraska Medical Center, Omaha.
  • VA Puget Sound Health Care System and University of Washington, Seattle.
  • VA Salt Lake City Healthcare System and University of Utah.
  • Washington VA Medical Center, Howard University, and Georgetown University, Washington, District of Columbia.

ORCID-Profile: Austin M Wheeler, Thomas R Riley, Tate M Johnson, Katherine D Wysham, Grant W Cannon, Gail Kerr, Dana P Ascherman, Paul Monach, Jill A Poole, Ted R Mikuls, Bryant R England

Förderung

  • NIH HHS
  • CSRD VA
  • RRD VA
  • NIOSH CDC HHS
  • BLRD VA
  • NIGMS NIH HHS
  • U.S. Department of Veterans Affairs
  • U.S. Department of Defense

Zitieren

APA

Wheeler, A. M., Baker, J. F., Riley, T. R., Johnson, T. M., Yang, Y., Roul, P., Wysham, K. D., Cannon, G. W., Kunkel, G., Kerr, G., Ascherman, D. P., Monach, P., Reimold, A., Matson, S., Poole, J. A., Duryee, M. J., Thiele, G. M., Mikuls, T. R., & England, B. R. (2025). Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease. Arthritis & Rheumatology, 77(8), 971-980. https://doi.org/10.1002/art.43149

Vancouver

Wheeler AM, Baker JF, Riley TR, Johnson TM, Yang Y, Roul P, et al. Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease. Arthritis & Rheumatology. 2025;77(8):971-980. doi:10.1002/art.43149

BibTeX
@article{Wheeler2025,
  author = {Wheeler, Austin M and Baker, Joshua F and Riley, Thomas R and Johnson, Tate M and Yang, Yangyuna and Roul, Punyasha and Wysham, Katherine D and Cannon, Grant W and Kunkel, Gary and Kerr, Gail and Ascherman, Dana P and Monach, Paul and Reimold, Andreas and Matson, Scott and Poole, Jill A and Duryee, Michael J and Thiele, Geoffrey M and Mikuls, Ted R and England, Bryant R},
  title = {Peripheral Biomarker Signatures in Rheumatoid Arthritis–Associated Interstitial Lung Disease},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  volume = {77},
  number = {8},
  pages = {971--980},
  doi = {10.1002/art.43149}
}
Kostenlos starten →